HK1111088A1 - Therapeutic uses of inhibitors of rtp801 rtp801 - Google Patents

Therapeutic uses of inhibitors of rtp801 rtp801

Info

Publication number
HK1111088A1
HK1111088A1 HK08105809.2A HK08105809A HK1111088A1 HK 1111088 A1 HK1111088 A1 HK 1111088A1 HK 08105809 A HK08105809 A HK 08105809A HK 1111088 A1 HK1111088 A1 HK 1111088A1
Authority
HK
Hong Kong
Prior art keywords
rtp801
inhibitors
therapeutic uses
therapeutic
rtp801 rtp801
Prior art date
Application number
HK08105809.2A
Other languages
English (en)
Inventor
Elena Feinstein
Klaus Giese
Jorg Kaufmann
Original Assignee
Quark Pharmaceuticals Inc
Silence Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quark Pharmaceuticals Inc, Silence Therapeutics Ag filed Critical Quark Pharmaceuticals Inc
Publication of HK1111088A1 publication Critical patent/HK1111088A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/054—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function
    • A01K2217/058—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function due to expression of inhibitory nucleic acid, e.g. siRNA, antisense
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
HK08105809.2A 2004-08-16 2008-05-26 Therapeutic uses of inhibitors of rtp801 rtp801 HK1111088A1 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP04019405 2004-08-16
US60198304P 2004-08-17 2004-08-17
US60466804P 2004-08-25 2004-08-25
US60978604P 2004-09-14 2004-09-14
US63865904P 2004-12-22 2004-12-22
US66423605P 2005-03-22 2005-03-22
US68894305P 2005-06-08 2005-06-08
PCT/US2005/029236 WO2006023544A2 (en) 2004-08-16 2005-08-16 Therapeutic uses of inhibitors of rtp801

Publications (1)

Publication Number Publication Date
HK1111088A1 true HK1111088A1 (en) 2008-09-05

Family

ID=35968125

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08105809.2A HK1111088A1 (en) 2004-08-16 2008-05-26 Therapeutic uses of inhibitors of rtp801 rtp801

Country Status (20)

Country Link
US (4) US7741299B2 (es)
EP (2) EP2319925B1 (es)
JP (1) JP4468989B2 (es)
KR (2) KR100939274B1 (es)
CN (1) CN101123994B (es)
AP (1) AP2007003921A0 (es)
AU (1) AU2005277508B2 (es)
BR (1) BRPI0514395A (es)
CA (1) CA2577423C (es)
DK (1) DK2319925T3 (es)
EA (1) EA012799B1 (es)
HK (1) HK1111088A1 (es)
IL (3) IL181238A (es)
MA (1) MA28802B1 (es)
MX (1) MX2007002043A (es)
NO (1) NO342934B1 (es)
NZ (1) NZ553162A (es)
PL (1) PL1791568T3 (es)
TN (1) TNSN07063A1 (es)
WO (1) WO2006023544A2 (es)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1527176E (pt) 2002-08-05 2007-04-30 Atugen Ag Novas formas de muléculas de arn de interferência
WO2004035615A2 (en) * 2002-10-18 2004-04-29 Atugen Ag Factor involved in metastasis and uses thereof
WO2005041748A2 (en) 2003-09-12 2005-05-12 Minnow Medical, Llc Selectable eccentric remodeling and/or ablation of atherosclerotic material
EA012799B1 (ru) * 2004-08-16 2009-12-30 Кварк Фармасьютикалс, Инк. Терапевтические применения ингибиторов rtp801
US9713730B2 (en) 2004-09-10 2017-07-25 Boston Scientific Scimed, Inc. Apparatus and method for treatment of in-stent restenosis
US8396548B2 (en) 2008-11-14 2013-03-12 Vessix Vascular, Inc. Selective drug delivery in a lumen
NZ553987A (en) 2004-09-28 2011-01-28 Quark Pharmaceuticals Inc Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
US7825099B2 (en) * 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
NL2000439C2 (nl) * 2006-01-20 2009-03-16 Quark Biotech Therapeutische toepassingen van inhibitoren van RTP801.
US7910566B2 (en) * 2006-03-09 2011-03-22 Quark Pharmaceuticals Inc. Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
US8019435B2 (en) 2006-05-02 2011-09-13 Boston Scientific Scimed, Inc. Control of arterial smooth muscle tone
WO2007141796A2 (en) * 2006-06-09 2007-12-13 Quark Pharmaceuticals, Inc. Therapeutic uses of inhibitors of rtp801l
JP2008167739A (ja) * 2006-06-14 2008-07-24 National Institute Of Advanced Industrial & Technology Ｒｎａ干渉効果が高い修飾型二本鎖ｒｎａ
ES2546773T3 (es) 2006-10-18 2015-09-28 Vessix Vascular, Inc. Energía de RF sintonizada y caracterización eléctrica de tejido para el tratamiento selectivo de tejidos diana
AU2007310991B2 (en) 2006-10-18 2013-06-20 Boston Scientific Scimed, Inc. System for inducing desirable temperature effects on body tissue
JP5479901B2 (ja) 2006-10-18 2014-04-23 べシックス・バスキュラー・インコーポレイテッド 身体組織に対する所望の温度作用の誘発
JP2010507387A (ja) * 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のｓｉＲＮＡおよびその使用方法
US7872119B2 (en) * 2007-02-26 2011-01-18 Quark Pharmaceuticals, Inc. Inhibitors of RTP801 and their use in disease treatment
US20100292301A1 (en) * 2007-02-28 2010-11-18 Elena Feinstein Novel sirna structures
US7812002B2 (en) * 2007-03-21 2010-10-12 Quark Pharmaceuticals, Inc. Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
JP2010527914A (ja) * 2007-04-26 2010-08-19 クォーク ファーマシューティカルズ インコーポレーティッド 呼吸器系への抑制性核酸分子の治療的送達
EP2170403B1 (en) * 2007-06-27 2014-04-16 Quark Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of pro-apoptotic genes
US20090062309A1 (en) * 2007-08-28 2009-03-05 Antonio Delgado-Almeida Therapeutic compositions for the treatment of cardiovascular diseases and methods for use therefor
CA2701845A1 (en) * 2007-10-03 2009-04-09 Quark Pharmaceuticals, Inc. Novel sirna structures
WO2009074990A2 (en) * 2007-12-12 2009-06-18 Quark Pharmaceuticals, Inc. Rtp801l sirna compounds and methods of use thereof
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof
JP2011517404A (ja) * 2008-03-20 2011-06-09 クォーク・ファーマシューティカルズ・インク ＲＴＰ８０１を阻害するための新規なｓｉＲＮＡ化合物
ES2565185T3 (es) * 2008-04-18 2016-04-01 Collplant Ltd. Métodos de generación y de uso del procolágeno
WO2009147684A2 (en) 2008-06-06 2009-12-10 Quark Pharmaceuticals, Inc. Compositions and methods for treatment of ear disorders
EP2323695B1 (en) 2008-08-19 2018-12-05 Nektar Therapeutics Complexes of small-interfering nucleic acids
WO2010048352A2 (en) * 2008-10-22 2010-04-29 Quark Pharmaceuticals, Inc. Methods for treating eye disorders
AU2009314133B2 (en) 2008-11-17 2015-12-10 Vessix Vascular, Inc. Selective accumulation of energy with or without knowledge of tissue topography
US9446194B2 (en) * 2009-03-27 2016-09-20 Dexcom, Inc. Methods and systems for promoting glucose management
US8916693B2 (en) 2009-09-17 2014-12-23 Nektar Therapeutics Monoconjugated chitosans as delivery agents for small interfering nucleic acids
DK2504435T3 (da) 2009-11-26 2019-12-09 Quark Pharmaceuticals Inc Sirna-forbindelser omfattende terminale substitutioner
WO2011072091A1 (en) 2009-12-09 2011-06-16 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the cns
WO2011084193A1 (en) 2010-01-07 2011-07-14 Quark Pharmaceuticals, Inc. Oligonucleotide compounds comprising non-nucleotide overhangs
CN103068330B (zh) 2010-04-09 2016-06-29 Vessix血管股份有限公司 用于治疗组织的功率发生和控制装置
US9192790B2 (en) 2010-04-14 2015-11-24 Boston Scientific Scimed, Inc. Focused ultrasonic renal denervation
US8473067B2 (en) 2010-06-11 2013-06-25 Boston Scientific Scimed, Inc. Renal denervation and stimulation employing wireless vascular energy transfer arrangement
US9408661B2 (en) 2010-07-30 2016-08-09 Patrick A. Haverkost RF electrodes on multiple flexible wires for renal nerve ablation
US9084609B2 (en) 2010-07-30 2015-07-21 Boston Scientific Scime, Inc. Spiral balloon catheter for renal nerve ablation
US9463062B2 (en) 2010-07-30 2016-10-11 Boston Scientific Scimed, Inc. Cooled conductive balloon RF catheter for renal nerve ablation
US9358365B2 (en) 2010-07-30 2016-06-07 Boston Scientific Scimed, Inc. Precision electrode movement control for renal nerve ablation
US9155589B2 (en) 2010-07-30 2015-10-13 Boston Scientific Scimed, Inc. Sequential activation RF electrode set for renal nerve ablation
US8974451B2 (en) 2010-10-25 2015-03-10 Boston Scientific Scimed, Inc. Renal nerve ablation using conductive fluid jet and RF energy
US9220558B2 (en) 2010-10-27 2015-12-29 Boston Scientific Scimed, Inc. RF renal denervation catheter with multiple independent electrodes
US9028485B2 (en) 2010-11-15 2015-05-12 Boston Scientific Scimed, Inc. Self-expanding cooling electrode for renal nerve ablation
US9089350B2 (en) 2010-11-16 2015-07-28 Boston Scientific Scimed, Inc. Renal denervation catheter with RF electrode and integral contrast dye injection arrangement
US9668811B2 (en) 2010-11-16 2017-06-06 Boston Scientific Scimed, Inc. Minimally invasive access for renal nerve ablation
US9326751B2 (en) 2010-11-17 2016-05-03 Boston Scientific Scimed, Inc. Catheter guidance of external energy for renal denervation
US9060761B2 (en) 2010-11-18 2015-06-23 Boston Scientific Scime, Inc. Catheter-focused magnetic field induced renal nerve ablation
US9023034B2 (en) 2010-11-22 2015-05-05 Boston Scientific Scimed, Inc. Renal ablation electrode with force-activatable conduction apparatus
US9192435B2 (en) 2010-11-22 2015-11-24 Boston Scientific Scimed, Inc. Renal denervation catheter with cooled RF electrode
CN103298939A (zh) 2010-12-06 2013-09-11 夸克医药公司 包含位置修饰的双链寡核苷酸化合物
US20120157993A1 (en) 2010-12-15 2012-06-21 Jenson Mark L Bipolar Off-Wall Electrode Device for Renal Nerve Ablation
US9220561B2 (en) 2011-01-19 2015-12-29 Boston Scientific Scimed, Inc. Guide-compatible large-electrode catheter for renal nerve ablation with reduced arterial injury
WO2013013156A2 (en) 2011-07-20 2013-01-24 Boston Scientific Scimed, Inc. Percutaneous devices and methods to visualize, target and ablate nerves
AU2012287189B2 (en) 2011-07-22 2016-10-06 Boston Scientific Scimed, Inc. Nerve modulation system with a nerve modulation element positionable in a helical guide
US9186210B2 (en) 2011-10-10 2015-11-17 Boston Scientific Scimed, Inc. Medical devices including ablation electrodes
US9420955B2 (en) 2011-10-11 2016-08-23 Boston Scientific Scimed, Inc. Intravascular temperature monitoring system and method
US10085799B2 (en) 2011-10-11 2018-10-02 Boston Scientific Scimed, Inc. Off-wall electrode device and methods for nerve modulation
US9364284B2 (en) 2011-10-12 2016-06-14 Boston Scientific Scimed, Inc. Method of making an off-wall spacer cage
US9162046B2 (en) 2011-10-18 2015-10-20 Boston Scientific Scimed, Inc. Deflectable medical devices
WO2013059202A1 (en) 2011-10-18 2013-04-25 Boston Scientific Scimed, Inc. Integrated crossing balloon catheter
MX356814B (es) 2011-11-03 2018-06-13 Quark Pharmaceuticals Inc Métodos y composiciones para neuroprotección.
CN104023662B (zh) 2011-11-08 2018-02-09 波士顿科学西美德公司 孔部肾神经消融
EP2776565A1 (en) 2011-11-08 2014-09-17 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the nervous system
WO2013074813A1 (en) 2011-11-15 2013-05-23 Boston Scientific Scimed, Inc. Device and methods for renal nerve modulation monitoring
US9119632B2 (en) 2011-11-21 2015-09-01 Boston Scientific Scimed, Inc. Deflectable renal nerve ablation catheter
US9265969B2 (en) 2011-12-21 2016-02-23 Cardiac Pacemakers, Inc. Methods for modulating cell function
WO2013096913A2 (en) 2011-12-23 2013-06-27 Vessix Vascular, Inc. Methods and apparatuses for remodeling tissue of or adjacent to a body passage
EP2797534A1 (en) 2011-12-28 2014-11-05 Boston Scientific Scimed, Inc. Device and methods for nerve modulation using a novel ablation catheter with polymeric ablative elements
US9050106B2 (en) 2011-12-29 2015-06-09 Boston Scientific Scimed, Inc. Off-wall electrode device and methods for nerve modulation
US10660703B2 (en) 2012-05-08 2020-05-26 Boston Scientific Scimed, Inc. Renal nerve modulation devices
US9890215B2 (en) * 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
US10321946B2 (en) 2012-08-24 2019-06-18 Boston Scientific Scimed, Inc. Renal nerve modulation devices with weeping RF ablation balloons
DK2895607T3 (da) 2012-09-12 2021-05-25 Quark Pharmaceuticals Inc Dobbeltstrengede oligonukleotidmolekyler til ddit4 og fremgangsmåder til anvendelse deraf
EP2895095A2 (en) 2012-09-17 2015-07-22 Boston Scientific Scimed, Inc. Self-positioning electrode system and method for renal nerve modulation
WO2014047411A1 (en) 2012-09-21 2014-03-27 Boston Scientific Scimed, Inc. System for nerve modulation and innocuous thermal gradient nerve block
US10549127B2 (en) 2012-09-21 2020-02-04 Boston Scientific Scimed, Inc. Self-cooling ultrasound ablation catheter
WO2014059165A2 (en) 2012-10-10 2014-04-17 Boston Scientific Scimed, Inc. Renal nerve modulation devices and methods
US9956033B2 (en) 2013-03-11 2018-05-01 Boston Scientific Scimed, Inc. Medical devices for modulating nerves
WO2014143571A1 (en) 2013-03-11 2014-09-18 Boston Scientific Scimed, Inc. Medical devices for modulating nerves
US9808311B2 (en) 2013-03-13 2017-11-07 Boston Scientific Scimed, Inc. Deflectable medical devices
US10265122B2 (en) 2013-03-15 2019-04-23 Boston Scientific Scimed, Inc. Nerve ablation devices and related methods of use
CN105473090B (zh) 2013-03-15 2019-05-03 波士顿科学国际有限公司 重建身体通道的组织或邻近身体通道的组织的方法及装置
JP6139772B2 (ja) 2013-03-15 2017-05-31 ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． 電極パッドと共に使用するための制御ユニットおよび漏電を推定するための方法
JP2016516804A (ja) 2013-04-17 2016-06-09 ファイザー・インク 心血管疾患を治療するためのｎ−ピペリジン−３−イルベンズアミド誘導体
CN105473092B (zh) 2013-06-21 2019-05-17 波士顿科学国际有限公司 具有可旋转轴的用于肾神经消融的医疗器械
JP2016523147A (ja) 2013-06-21 2016-08-08 ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． 同乗型電極支持体を備えた腎除神経バルーンカテーテル
US9707036B2 (en) 2013-06-25 2017-07-18 Boston Scientific Scimed, Inc. Devices and methods for nerve modulation using localized indifferent electrodes
AU2014284558B2 (en) 2013-07-01 2017-08-17 Boston Scientific Scimed, Inc. Medical devices for renal nerve ablation
CN105377170A (zh) 2013-07-11 2016-03-02 波士顿科学国际有限公司 具有可伸展电极组件的医疗装置
US10660698B2 (en) 2013-07-11 2020-05-26 Boston Scientific Scimed, Inc. Devices and methods for nerve modulation
EP3049007B1 (en) 2013-07-19 2019-06-12 Boston Scientific Scimed, Inc. Spiral bipolar electrode renal denervation balloon
CN105392435B (zh) 2013-07-22 2018-11-09 波士顿科学国际有限公司 具有扭绞球囊的肾神经消融导管
WO2015013205A1 (en) 2013-07-22 2015-01-29 Boston Scientific Scimed, Inc. Medical devices for renal nerve ablation
WO2015027096A1 (en) 2013-08-22 2015-02-26 Boston Scientific Scimed, Inc. Flexible circuit having improved adhesion to a renal nerve modulation balloon
EP3041425B1 (en) 2013-09-04 2022-04-13 Boston Scientific Scimed, Inc. Radio frequency (rf) balloon catheter having flushing and cooling capability
CN105530885B (zh) 2013-09-13 2020-09-22 波士顿科学国际有限公司 具有气相沉积覆盖层的消融球囊
CN105592778B (zh) 2013-10-14 2019-07-23 波士顿科学医学有限公司 高分辨率心脏标测电极阵列导管
US11246654B2 (en) 2013-10-14 2022-02-15 Boston Scientific Scimed, Inc. Flexible renal nerve ablation devices and related methods of use and manufacture
AU2014334574B2 (en) 2013-10-15 2017-07-06 Boston Scientific Scimed, Inc. Medical device balloon
US9770606B2 (en) 2013-10-15 2017-09-26 Boston Scientific Scimed, Inc. Ultrasound ablation catheter with cooling infusion and centering basket
US10945786B2 (en) 2013-10-18 2021-03-16 Boston Scientific Scimed, Inc. Balloon catheters with flexible conducting wires and related methods of use and manufacture
US10271898B2 (en) 2013-10-25 2019-04-30 Boston Scientific Scimed, Inc. Embedded thermocouple in denervation flex circuit
EP3091922B1 (en) 2014-01-06 2018-10-17 Boston Scientific Scimed, Inc. Tear resistant flex circuit assembly
US11000679B2 (en) 2014-02-04 2021-05-11 Boston Scientific Scimed, Inc. Balloon protection and rewrapping devices and related methods of use
WO2015119890A1 (en) 2014-02-04 2015-08-13 Boston Scientific Scimed, Inc. Alternative placement of thermal sensors on bipolar electrode
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CA3010056A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
JP2019535839A (ja) 2016-11-29 2019-12-12 ピュアテック ヘルス エルエルシー 治療剤の送達のためのエクソソーム
KR101933217B1 (ko) 2017-12-28 2018-12-27 (주) 에빅스젠 피부 염증 억제용 펩티드 및 이를 포함하는 피부 염증 예방 또는 치료용 조성물
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4925678A (en) 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
US5080646A (en) 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5270030A (en) 1988-12-29 1993-12-14 Bio-Technology General Corp. Fibrin binding domain polypeptide and method of producing
US5225347A (en) 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Therapeutic ribozyme compositions and expression vectors
US5167616A (en) 1989-12-14 1992-12-01 Alza Corporation Iontophoretic delivery method
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5225182A (en) 1991-10-31 1993-07-06 Sharma Yash P Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system
US6372249B1 (en) 1991-12-16 2002-04-16 Baylor College Of Medicine Senscent cell-derived inhibitors of DNA synthesis
EP0618925B2 (en) 1991-12-24 2012-04-18 Isis Pharmaceuticals, Inc. Antisense oligonucleotides
EP0642589A4 (en) 1992-05-11 1997-05-21 Ribozyme Pharm Inc METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1994024704A1 (en) * 1993-04-12 1994-10-27 Bolger Justin C Area bonding conductive adhesive preforms
GB9402161D0 (en) * 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
ES2301183T3 (es) 1996-12-03 2008-06-16 Amgen Fremont Inc. Anticuerpo completamente humano que se une al receptor del egfr.
RU2224766C2 (ru) 1997-04-14 2004-02-27 Микромет Аг Способ получения рецепторов для человеческих антигенов и их применение
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20030104973A1 (en) 1997-08-21 2003-06-05 Quark Biotech, Inc. Hypoxia-regulated genes
US7973156B2 (en) 1997-08-21 2011-07-05 Quark Pharmaceuticals Inc. Hypoxia-regulated genes
ATE293633T1 (de) * 1997-08-21 2005-05-15 Quark Biotech Inc Hypoxie-regulierte gene
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
DE19816395A1 (de) 1998-04-03 1999-10-07 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Ovar-Normalgewebe
US6399178B1 (en) * 1998-07-20 2002-06-04 Amerasia International Technology, Inc. Rigid adhesive underfill preform, as for a flip-chip device
US6228585B1 (en) 1998-09-04 2001-05-08 Washington University Gene markers for chronic mucosal injury
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
EP1173477A4 (en) 1999-04-09 2003-02-26 Human Genome Sciences Inc 49 HUMAN SECRETED PROTEINS
JP2003516114A (ja) 1999-06-11 2003-05-13 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ５０個のヒト分泌タンパク質
WO2001005998A1 (en) 1999-07-16 2001-01-25 Human Genome Sciences, Inc. Follistatin-3
EP1248798A2 (en) 1999-08-18 2002-10-16 Fraunhofer-Gesellschaft Zur Förderung Der Angewandten Forschung E.V. Human dna sequences
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
DE10160151A1 (de) 2001-01-09 2003-06-26 Ribopharma Ag Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
WO2001070979A2 (en) 2000-03-21 2001-09-27 Millennium Pharmaceuticals, Inc. Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer
IL151928A0 (en) 2000-03-30 2003-04-10 Whitehead Biomedical Inst Rna sequence-specific mediators of rna interference
EP1274714A2 (en) 2000-04-06 2003-01-15 Genetics Institute, LLC Polynucleotides encoding novel secreted proteins
US6727066B2 (en) 2000-07-28 2004-04-27 Incyte Corporation Genes expressed in treated human C3A liver cell cultures
US6673545B2 (en) 2000-07-28 2004-01-06 Incyte Corporation Prostate cancer markers
US6673549B1 (en) 2000-10-12 2004-01-06 Incyte Corporation Genes expressed in C3A liver cell cultures treated with steroids
EP1325120A4 (en) 2000-10-12 2005-05-25 Nuvelo Inc NUCLEIC ACIDS AND POLYPEPTIDES
US20020137077A1 (en) 2000-10-25 2002-09-26 Hopkins Christopher M. Genes regulated in activated T cells
ES2215494T5 (es) 2000-12-01 2017-12-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Moléculas de RNA pequeñas que median la interferencia de RNA
AU2002220920A1 (en) 2000-12-08 2002-06-18 Oxford Biomedica (Uk) Limited Method for identification of genes involved in specific diseases
US20030165864A1 (en) 2001-01-16 2003-09-04 Lasek Amy W. Genes regulated by DNA methylation in tumor cells
SG106054A1 (en) * 2001-04-17 2004-09-30 Micron Technology Inc Method and apparatus for package reduction in stacked chip and board assemblies
WO2003070910A2 (en) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20040019001A1 (en) 2002-02-20 2004-01-29 Mcswiggen James A. RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
US7125663B2 (en) 2001-06-13 2006-10-24 Millenium Pharmaceuticals, Inc. Genes, compositions, kits and methods for identification, assessment, prevention, and therapy of cervical cancer
KR20040029380A (ko) 2001-07-25 2004-04-06 시바 스페셜티 케미칼스 홀딩 인크. 퍼플루오로알킬 치환된 아민, 산, 아미노산 및 티오에테르산
WO2003010205A1 (en) 2001-07-26 2003-02-06 Duke University Medical Center Genes induced by hypoxia
US20040063654A1 (en) 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
EP1432724A4 (en) 2002-02-20 2006-02-01 Sirna Therapeutics Inc RNA inhibition mediated inhibition of MAP KINASE GENES
JP2003259877A (ja) 2002-03-11 2003-09-16 Sumitomo Pharmaceut Co Ltd 肝線維症疾患マーカーおよびその利用
AU2003240495A1 (en) 2002-06-04 2003-12-19 Incyte Corporation Diagnostics markers for lung cancer
PT1527176E (pt) 2002-08-05 2007-04-30 Atugen Ag Novas formas de muléculas de arn de interferência
JP2004121218A (ja) 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk 気管支喘息または慢性閉塞性肺疾患の検査方法
EP2311978A1 (en) 2002-08-20 2011-04-20 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
US20070224201A1 (en) 2002-10-02 2007-09-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2004035615A2 (en) * 2002-10-18 2004-04-29 Atugen Ag Factor involved in metastasis and uses thereof
AU2003303144A1 (en) 2002-10-18 2004-07-29 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2322200A3 (en) 2002-10-29 2011-07-27 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004042024A2 (en) * 2002-11-01 2004-05-21 The Trustees Of The University Of Pennsylvania COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF HIF-1 ALPHA
US9150605B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
EP1560931B1 (en) 2002-11-14 2011-07-27 Dharmacon, Inc. Functional and hyperfunctional sirna
AU2003294324A1 (en) 2002-11-18 2004-06-15 Fox Chase Cancer Center Compositions and methods for the treatment of cancer, screening of putative anti-cancer compounds, and assessing cancer progression
JP4652325B2 (ja) 2003-02-21 2011-03-16 ユニバーシティ オブ ユタ リサーチ ファウンデイション 虚血性疾患用の低酸素状態誘導可能ｖｅｇｆプラスミド
EP2233926A3 (en) 2003-04-01 2011-01-12 The Johns Hopkins University Breast Endothelial Cell Expression Patterns
WO2005016000A1 (en) 2003-08-05 2005-02-24 Avalon Pharmaceuticals Derivatives of cyclic quinone and uses thereof
EA012799B1 (ru) 2004-08-16 2009-12-30 Кварк Фармасьютикалс, Инк. Терапевтические применения ингибиторов rtp801
NZ553987A (en) 2004-09-28 2011-01-28 Quark Pharmaceuticals Inc Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
US7825099B2 (en) 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
NL2000439C2 (nl) * 2006-01-20 2009-03-16 Quark Biotech Therapeutische toepassingen van inhibitoren van RTP801.
US7910566B2 (en) 2006-03-09 2011-03-22 Quark Pharmaceuticals Inc. Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
WO2008054534A2 (en) 2006-05-11 2008-05-08 Quark Pharmaceuticals, Inc. Screening systems utilizing rtp801
WO2007141796A2 (en) * 2006-06-09 2007-12-13 Quark Pharmaceuticals, Inc. Therapeutic uses of inhibitors of rtp801l
DE102006031683A1 (de) * 2006-07-08 2008-01-17 Zf Friedrichshafen Ag Verfahren zum Betreiben eines Antriebsstrangs
US7872119B2 (en) 2007-02-26 2011-01-18 Quark Pharmaceuticals, Inc. Inhibitors of RTP801 and their use in disease treatment
JP2011517404A (ja) 2008-03-20 2011-06-09 クォーク・ファーマシューティカルズ・インク ＲＴＰ８０１を阻害するための新規なｓｉＲＮＡ化合物
KR20100057710A (ko) 2008-11-10 2010-06-01 삼성전자주식회사 발광 다이오드 및 이를 포함하는 백라이트 유니트

Also Published As

Publication number Publication date
IL181238A (en) 2016-02-29
EP2319925B1 (en) 2018-07-25
US20060217329A1 (en) 2006-09-28
US8642571B2 (en) 2014-02-04
US7741299B2 (en) 2010-06-22
NO342934B1 (no) 2018-09-03
PL1791568T3 (pl) 2013-01-31
CN101123994B (zh) 2012-11-14
US8309532B2 (en) 2012-11-13
US8168607B2 (en) 2012-05-01
IL212985A0 (en) 2011-07-31
NO20071240L (no) 2007-05-16
BRPI0514395A (pt) 2008-06-10
US20130095117A1 (en) 2013-04-18
EP2319925A3 (en) 2011-09-21
KR100939274B1 (ko) 2010-01-29
IL243669B (en) 2018-11-29
KR20070050088A (ko) 2007-05-14
IL181238A0 (en) 2007-07-04
TNSN07063A1 (fr) 2008-06-02
CA2577423A1 (en) 2006-03-02
CA2577423C (en) 2012-11-06
US20110028532A1 (en) 2011-02-03
AU2005277508A1 (en) 2006-03-02
MX2007002043A (es) 2007-10-11
DK2319925T3 (da) 2018-11-05
KR20090115901A (ko) 2009-11-09
AP2007003921A0 (en) 2007-02-28
JP4468989B2 (ja) 2010-05-26
EP2319925A2 (en) 2011-05-11
EP1791568A4 (en) 2008-12-10
WO2006023544A2 (en) 2006-03-02
EP1791568B1 (en) 2012-08-15
US20110117102A1 (en) 2011-05-19
AU2005277508B2 (en) 2011-04-14
JP2008510019A (ja) 2008-04-03
MA28802B1 (fr) 2007-08-01
WO2006023544A3 (en) 2007-05-31
EA200700333A1 (ru) 2007-10-26
EP1791568A2 (en) 2007-06-06
EA012799B1 (ru) 2009-12-30
NZ553162A (en) 2010-03-26
CN101123994A (zh) 2008-02-13
KR101094617B1 (ko) 2011-12-15

Similar Documents

Publication Publication Date Title
IL212985A0 (en) Therapeutic uses of inhibitors of rtp801
IL211835A0 (en) Therapeutic uses of inhibitors of rtp801
EP1756092A4 (en) NEW INHIBITORS OF RHO-KINASEN
EP1753428A4 (en) INHIBITORS OF KINASES AS THERAPEUTIC AGENTS
PT1802579E (pt) Derivados da 3-arilaminopiridina
EP2026843A4 (en) THERAPEUTIC USES OF RTP801L INHIBITORS
HK1119696A1 (en) Pyridopyrimidinone inhibitors of pi3k pi3k
EP1789086A4 (en) PROLONGED TREATMENT OF MULTIPLE SCLEROSIS
EP2068864A4 (en) THERAPEUTIC USES OF UROLITHINS
EP1718611A4 (en) 3-3-DI-SUBSTITUTED OXINDOLES AS INHIBITORS OF INITIATION OF TRANSLATION
HK1109332A1 (zh) 藻毒素的經皮給藥
EP1789027A4 (en) Therapeutic Use of Anti- TF Antigen Antibodies
GB0305150D0 (en) Use of therapeutic compounds
PL1740204T3 (pl) Lecznicze zastosowanie alfa-mannozydazy
EP1740541A4 (en) THERAPEUTIC FORMULATIONS OF DESOXYEPOTHILONES
HK1111599A1 (en) Pharmaceutical compositions for the treatment of cellulite
GB0426196D0 (en) Methods of treatment
ZA200804266B (en) Therapeutic uses of steroidal compounds
PT1879609E (pt) Utilização de histionas para fins terapêuticos
GB0417560D0 (en) Therapeutic compounds
HU0400952D0 (en) Treatment of anus-cancer
IL195722A0 (en) Therapeutic uses of inhibitors of rtp801l
IL182987A0 (en) Treatment of inflammation
GB0422012D0 (en) Methods of treatment
LT1740204T (lt) Medicininis alfa-manozidazės panaudojimas

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210807